Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine

Human Vaccines

Volumn 4, Issue 1, 2008, Pages 50-53

  Lin, Tzou Yien ^a,c   Wang, Ying Hsiang ^a   Huang, Yhu Chering ^a   Chiu, Cheng Hsun ^a   Pen, Yi Lin ^a   Tang, Haiwen ^b   Hoet, Bernard ^b   Bock, Hans L ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NONE   (Taiwan)

Author keywords

Booster; Diphtheria; Pertussis; Tetanus; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ORAL POLIOMYELITIS VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ARTICLE; DIPHTHERIA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; POLIOMYELITIS; SCHOOL CHILD; SIDE EFFECT; TAIWAN; TETANUS; VACCINATION;

EID: 44649095664     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.1.4935     Document Type: Article

References (29)

1. Campins-Mart M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, Mertsola J, Oselka G, Wardi J, Wirsing von König CH, Zeppk F. International consensus group on pertussis immunisation: Recommendations are needed for adolescent and adult pertussis immunisation: Rationale and strategies for consideration. Vaccine 2001; 20:641-6.
2. von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744-50.
3. Cherry JD. The epidemiology of pertussis: A comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422-7.
4. The Australian Immunisation Handbook. 8th ed. National Health and Medical Research Council, 2003.
5. Centers for Disease Control and Prevention. Recommended childhood immunization schedule-United States 2001. MMWR 2001; 50:7-10.
6. Helwig H, Mertsola J, Harvey D, Nicolopoulos D, Schaack JC, Sedlak W. Childhood immunisation in the European Union: Confederation of european specialists in paediatrics (CESP). Eur J Pediatr 1998; 157:676-80.
7. Chiu TF, Lee CY, Lee PI, Lu CY, Lin HC, Huang LM. Pertussis seroepidemiology in Taipei. J Formos Med Assoc 2000; 99:224-8.
8. Lin PY, Chiu CH, Wang YH, Su LH, Chia JH, Huang YC, Chung PW, Wu TL, Lin TY. Bordetella pertussis infection in northern Taiwan, 1997-2001. J Microbiol Immunol Infect 2004; 37:288-94.
9. Edwards KM, Decker MD, Graham BS, Mezzaresta J, Scott J, Hackell J. Adult immunization with acellular pertussis vaccine. JAMA 1993; 269:53-6.
10. Ruuskanen O, Noel A, Putto-Laurila A, Petre J, Capiau C, Delem A, Vandevoorde D, Simoen E, Teuwen DE, Bogaerts H. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991; 9:117-21.
11. Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME. Comparison of a three-component acellular pertussis vaccine wirh a whole-cell pertussis vaccine in 4- through 6-year-old children. Arch Pediatr Adolescent Med 1994; 148:503-7.
12. Bernstein HH, Rothstein EP, Reisinger KS, Arbeter AM, Fontata ME, Jacobs JM, Long SS, Rathfon H, Crayne O, et al. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. Pediatrics 1994; 93:656-9.
13. Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous hemagglutinin and 69 kDa outer membrane protein as a booster in children. Eur J Pediatr 1993; 152:478-83.
14. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and wholecell pertussis vaccines as a booster dose: A multicentre study. Pediatrics 1994; 93:37-43.
15. Pichichero M, Deloria M, Rennels M, Anderson E, Edwards K, Decker M, Englund J, Steinhoff M, Deforest A, Meade B. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100:772-88.
16. Schmitt HJ, Beutel K, Schuind A, Kunf M, Wagner S, Muschenbom S, Bogaerts H, Bock HL, Clemens R. Reactogenicity and Immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997; 130:616-23.
17. Vergara R, Tregnaghi M, Ussher J, Navarro S, Ruttimann R, Potin M, Wolter J. Schuerman L. Reduced Antigen content diphtheria tetanus acellular pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005; 164:377-82.
18. Dagan R, Igbaria K, Piglansky L, Van Brusteghem F, Melot V, Kaufhold A. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age. Vaccine 1999; 17:2620-7.
19. Saenger R, Wolter J, Schuerman L. A reduced-antigen diphtheria tetanus acellular pertussis-IPV vaccine for booster vaccination of 4 to 8 year old children. Proc 21st Annu Meet Eur Soc Paediatr Infect Dis (Espid) Taormina 2003; 284.
20. Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, Poovorawan Y. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003; 21:4194-200.
21. Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter M, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004; 23:336-42.
22. Collins CL, Salt P, McCathy N, Chantler T, Iane L, Hemme F, Diggle L, Buttery J, Kitchin NRE, Moxon ER, Pollard AJ. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 2004; 22:4262-9.
23. Huang LK, Chang LY, Tang H, Bock HL, Lu CY, Huang FY, Kin TY, Lee CY. Immunogenicity and reactogenicity of a reduced antigen content diphtheria tetanus acellular pertussis vaccine in healthy Taiwanese children and adolescents. Journal of Adolescent Health 2005; 37:517.e1-517.e5.
24. Chan SH, Tan PTN, Han HH, Bock HL. Immunogenicity and reactogenicity of Immunogenicity and Reactogenicity of a reduced antigen content diphtheria tetanus acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singapore Med J 2006; 47:286-90.
25. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000; 106:E51.
26. Deloria MA, Blackwelder WC, Decker MD, Englund JA, Steinhoff MC, Pichichero ME, Rennels MB, Anderson EL, Edwards KM. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995; 96:592-4.
27. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3:93-97.
28. Salmaso S, Mastrantonio P, Tozzi Ae, Stefanelli P, Anemona A, Ciofi Degli Atti MI, Giammanco A. Stage III working group: Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: The Italian experience. Pediatrics 2001; 108:E81.
29. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, Heininger U, Schellekens J, Tan T, von Konig CH, Plotkin S. Global pertussis initiative: New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802-9.